Investigations into the CSF3R gene may help lead to better classification and precise treatment of AML.
Targeted delivery of nanoparticles may reduce systemic and CNS toxicity in spinal cord tumors.
Researchers believe an assay may be used to detect and monitor dynamics of genetic mutations of patients treated with immunotherapy.
The STRIvE-01 study explored the safety of CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors.
Researchers report that the same driving force that makes Zika so detrimental to unborn babies gives it promise as a cancer treatment.
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma.
Korean investigators concluded that, in terms of recurrence risk, a qualified high-volume surgeon may be optimal for performing the initial surgery in this setting.
A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell–based immunotherapies.
The CoGAPS gene activity algorithm may elucidate molecular changes that occur as H&N tumors acquire resistance to cetuximab, says a Johns Hopkins team.
Oncologists should refer patients who want traditional genetic counseling and/or have preexisting psychosocial factors that would increase risk of an adverse psychological outcome of counseling.